Synlogic announces data presentations from five programs at the 2022 synthetic biology: engineering, evolution & design (seed) conference

Cambridge, mass., april 26, 2022 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced its planned presentations at the 2022 synthetic biology: engineering, evolution & design (seed) conference being held may 2-5, 2022, in arlington, va. the oral presentation outlines synlogic's progress in developing synthetic biotic drug candidates for rare metabolic diseases phenylketonuria (pku) and homocystinuria (hcu), both inborn errors of metabolism. the poster presentations highlight preclinical and clinical data across five different synlogic programs. presentation details are provided below.
SYBX Ratings Summary
SYBX Quant Ranking